EBV Related PTCL clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
open to eligible people ages 18 years and up
A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas
at UC Irvine UCLA UCSF
Last updated: